Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of QPX7728 Alone and with QPX2014 in Healthy Adults
NCT04380207Phase 1Completed
- Sponsor
- Qpex Biopharma
- Start
- Nov 2020
- Primary completion
- Aug 2022
- Modality
- Reversible Covalent Inhibitors
- Countries
- 2
01
Overview
Phase 1, randomised, double-blind trial of xeruborbactam in bacterial infection (3 arms), sponsored by Qpex Biopharma. Primary endpoints: Incidence of Treatment-Emergent Adverse events (AEs) up to 21 days, Number of patients with changes from baseline in safety parameters up to 21 days and 4 more. Started Nov 2020; status: completed.
02
Drugs
xeruborbactam
03
Conditions
bacterial infection
Beyond the preview
Go deeper on NCT04380207.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04380207.